Psychopharmacology

, Volume 174, Issue 4, pp 571–577

Changes in food reward following smoking cessation: a pharmacogenetic investigation

Authors

    • Department of Psychiatry, Abramson Cancer CenterUniversity of Pennsylvania
  • Wade Berrettini
    • Department of Psychiatry, Abramson Cancer CenterUniversity of Pennsylvania
  • Angela Pinto
    • Department of Psychiatry, Abramson Cancer CenterUniversity of Pennsylvania
  • Freda Patterson
    • Department of Psychiatry, Abramson Cancer CenterUniversity of Pennsylvania
  • Susan Crystal-Mansour
    • Westat
  • E. Paul Wileyto
    • Department of Psychiatry, Abramson Cancer CenterUniversity of Pennsylvania
  • Stephanie L. Restine
    • Molecular Diagnosis and Genotyping Facility, Abramson Cancer CenterUniversity of Pennsylvania
  • Debra G. B. Leonard
    • Molecular Diagnosis and Genotyping Facility, Abramson Cancer CenterUniversity of Pennsylvania
  • Peter G. Shields
    • Department of OncologyGeorgetown University
  • Leonard H. Epstein
    • Department of Pediatrics, School of Medicine and Biomedical SciencesState University of New York
Original Investigation

DOI: 10.1007/s00213-004-1823-9

Cite this article as:
Lerman, C., Berrettini, W., Pinto, A. et al. Psychopharmacology (2004) 174: 571. doi:10.1007/s00213-004-1823-9

Abstract

Rationale

Despite the high prevalence and public health significance of weight gain following smoking cessation, little is known about the underlying bio-behavioral mechanisms or effective therapies.

Objectives

We evaluated the effects of bupropion on food reward following smoking abstinence and the moderating influence of genotype.

Methods

Seventy-one smokers of European ancestry were genotyped for the dopamine D2 receptor (DRD2) Taq1 polymorphism and randomized to treatment with bupropion (300 mg) or placebo for smoking cessation. Subjects participated in two behavioral laboratory sessions during which the rewarding value of food was assessed using a behavioral economics measure: session 1 occurred prior to medication and before cessation of smoking; session 2 occurred following 3 weeks of medication and 1 week of sustained abstinence.

Results

Carriers of the DRD2 A1 minor allele exhibited significant increases in the rewarding value of food following abstinence from smoking, and these effects were attenuated by bupropion treatment (P=0.03 for medication by genotype interaction). Further, higher levels of food reward at session 2 (post-quit) predicted a significant increase in weight by 6-month follow-up in the placebo group, but not in the bupropion-treated group (P=0.006 for medication by food reward interaction).

Conclusions

These results provide new evidence that the increase in body weight that occurs following smoking cessation is related to increases in food reward, and that food reward is partly determined by genetic factors. Bupropion’s efficacy in attenuating abstinence-induced weight gain may be attributable, in part, to decreasing food reward.

Keywords

NicotineFood rewardSmoking cessationTreatment

Copyright information

© Springer-Verlag 2004